235 related articles for article (PubMed ID: 38443899)
1. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Cytokine and soluble programmed death-ligand 1 levels in serum and plasma of cancer patients treated with immunotherapy: Preanalytical and analytical considerations.
Cappelletto E; Fasiolo LT; Salizzato V; Piccin L; Fabozzi A; Contato A; Bianco PD; Pasello G; Chiarion-Sileni V; Gion M; Fabricio ASC
Int J Biol Markers; 2024 Mar; 39(1):9-22. PubMed ID: 38407953
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
5. Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
Oyanagi J; Koh Y; Sato K; Teraoka S; Tokudome N; Hayata A; Akamatsu H; Ozawa Y; Nakanishi M; Ueda H; Yamamoto N
Clin Lung Cancer; 2021 Nov; 22(6):e833-e841. PubMed ID: 34049821
[TBL] [Abstract][Full Text] [Related]
6. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.
Naqash AR; McCallen JD; Mi E; Iivanainen S; Marie MA; Gramenitskaya D; Clark J; Koivunen JP; Macherla S; Jonnalagadda S; Polsani S; Jiwani RA; Hafiz M; Muzaffar M; Brunetti L; Stroud CRG; Walker PR; Wang K; Chung Y; Ruppin E; Lee SH; Yang LV; Pinato DJ; Lee JS; Cortellini A
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852738
[TBL] [Abstract][Full Text] [Related]
7. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
Yang Q; Chen M; Gu J; Niu K; Zhao X; Zheng L; Xu Z; Yu Y; Li F; Meng L; Chen Z; Zhuo W; Zhang L; Sun J
Front Immunol; 2021; 12():665133. PubMed ID: 33936103
[TBL] [Abstract][Full Text] [Related]
8. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
9. Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12.
Xu Y; Ding L; Li H; Peng Z; Ding K; Huang Z; Zhou Z; Xie M; Yan J; Feng S; Fan Y
Front Immunol; 2023; 14():1194123. PubMed ID: 37359565
[TBL] [Abstract][Full Text] [Related]
10. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
Cheng Y; Wang C; Wang Y; Dai L
Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
12. Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Jung EH; Jang HR; Kim SH; Suh KJ; Kim YJ; Lee JH; Chung JH; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
Thorac Cancer; 2021 Mar; 12(5):619-630. PubMed ID: 33458968
[TBL] [Abstract][Full Text] [Related]
13. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
Front Immunol; 2022; 13():987568. PubMed ID: 36159840
[TBL] [Abstract][Full Text] [Related]
14. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract][Full Text] [Related]
15. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Takam Kamga P; Mayenga M; Sebane L; Costantini A; Julie C; Capron C; Parent F; Seferian A; Guettier C; Emile JF; Giroux Leprieur E
Lung Cancer; 2024 Feb; 188():107447. PubMed ID: 38176297
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
17. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.
Sanmamed MF; Perez-Gracia JL; Schalper KA; Fusco JP; Gonzalez A; Rodriguez-Ruiz ME; Oñate C; Perez G; Alfaro C; Martín-Algarra S; Andueza MP; Gurpide A; Morgado M; Wang J; Bacchiocchi A; Halaban R; Kluger H; Chen L; Sznol M; Melero I
Ann Oncol; 2017 Aug; 28(8):1988-1995. PubMed ID: 28595336
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
[TBL] [Abstract][Full Text] [Related]
19. Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Himuro H; Nakahara Y; Igarashi Y; Kouro T; Higashijima N; Matsuo N; Murakami S; Wei F; Horaguchi S; Tsuji K; Mano Y; Saito H; Azuma K; Sasada T
Cancer Immunol Immunother; 2023 Aug; 72(8):2829-2840. PubMed ID: 37188764
[TBL] [Abstract][Full Text] [Related]
20. Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China.
Wang Y; Lu J; Wu C; Fei F; Chu Z; Lu P
Front Immunol; 2023; 14():1276107. PubMed ID: 38124739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]